In the phase III VERONA trial, venetoclax (Venclexta) in combination with azacitidine failed to improve overall survival in newly diagnosed patients with higher-risk myelodysplastic syndromes, AbbVie ...

"Aptose is incredibly grateful for Hanmi's continued support tuspetinib,” said William G. Rice, Ph.D., Chairman, President ...

Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins miple ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins ...

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...